CN116261450A - 癌症肽疫苗及其制备方法 - Google Patents

癌症肽疫苗及其制备方法 Download PDF

Info

Publication number
CN116261450A
CN116261450A CN202180066525.3A CN202180066525A CN116261450A CN 116261450 A CN116261450 A CN 116261450A CN 202180066525 A CN202180066525 A CN 202180066525A CN 116261450 A CN116261450 A CN 116261450A
Authority
CN
China
Prior art keywords
peptide
seq
cancer
leu
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180066525.3A
Other languages
English (en)
Chinese (zh)
Inventor
小高和彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BrightPath Biotherapeutics Co Ltd
Original Assignee
Green-Peptide Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green-Peptide Co Ltd filed Critical Green-Peptide Co Ltd
Publication of CN116261450A publication Critical patent/CN116261450A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180066525.3A 2020-07-29 2021-07-28 癌症肽疫苗及其制备方法 Pending CN116261450A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-128412 2020-07-29
JP2020128412 2020-07-29
PCT/JP2021/027832 WO2022025093A1 (ja) 2020-07-29 2021-07-28 がんペプチドワクチンおよびその製造方法

Publications (1)

Publication Number Publication Date
CN116261450A true CN116261450A (zh) 2023-06-13

Family

ID=80035678

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066525.3A Pending CN116261450A (zh) 2020-07-29 2021-07-28 癌症肽疫苗及其制备方法

Country Status (4)

Country Link
US (1) US20230321241A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022025093A1 (cg-RX-API-DMAC7.html)
CN (1) CN116261450A (cg-RX-API-DMAC7.html)
WO (1) WO2022025093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024149926A (ja) * 2021-08-06 2024-10-23 ブライトパス・バイオ株式会社 がんペプチドワクチンカクテル製剤、及びその製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120231A2 (en) * 2014-02-06 2015-08-13 Xeris Phrmaceuticals, Inc. Stable peptide formulations and methods for preparation

Also Published As

Publication number Publication date
US20230321241A1 (en) 2023-10-12
JPWO2022025093A1 (cg-RX-API-DMAC7.html) 2022-02-03
WO2022025093A1 (ja) 2022-02-03

Similar Documents

Publication Publication Date Title
KR20220044481A (ko) 암 면역요법을 위한 조성물 및 방법
JP6224268B2 (ja) 子宮内膜癌の治療において使用するためのデュオカルマイシンadc
EP3773714A1 (en) Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
ES2825080T3 (es) Anticuerpos humanizados contra CEACAM1
EP3876978A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US9757439B2 (en) Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent
KR20170003575A (ko) 비-소세포 폐암을 치료하기 위한 항-b7-h1 및 항-ctla-4 항체
EP3545969A1 (en) Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
KR20180038550A (ko) 다양한 암의 면역요법 치료에서의 사용을 위한 신규 펩티드, 펩티드의 조합 및 골격
KR20180085725A (ko) 다양한 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
JP2023036999A (ja) 免疫応答を調節するためのオキサビシクロヘプタン
KR102043725B1 (ko) 뇌 전이 치료를 위한 치료용 다중 펩타이드 t 특이적 면역 요법
KR20200112904A (ko) 암을 치료하는 조성물 및 방법
KR102921677B1 (ko) 수용성 보조제
EP2591799A1 (en) Cancer peptide vaccine
US20230321241A1 (en) Cancer peptide vaccine and method of preparing the same
KR20090112590A (ko) 백신을 위한 인간 조직 적합성 항원(hla) 종류 i 또는 ii 분자에 결합하는 종양 관련 펩티드의 새로운 제형
KR20250092133A (ko) 면역억제성 종양미세환경을 조절하는 항체-펩타이드 융합체 및 이의 항암용도
JP2024149926A (ja) がんペプチドワクチンカクテル製剤、及びその製造方法
US20250296966A1 (en) Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
EP4338742A1 (en) Application of hydroxyprogesterone caproate in enhancing tumor treatment effect
EP4491194A1 (en) Triple combination drug dosing therapy for head and neck cancer treatment
CN111727060B (zh) 治疗癌症的激动剂抗PD-1抗体与GnRH激动剂或GnRH拮抗剂的组合
CN116685352A (zh) 用gm-csf拮抗剂治疗癌症
JP2021504378A (ja) 改良されたがんの処置

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination